Fatty acids and their metabolism critically regulate podocyte survival by Kampe, Kapil Dev
	
  
	
  
	
  
Fatty	
  Acids	
  and	
  their	
  Metabolism	
  Critically	
  
Regulate	
  Podocyte	
  Survival	
  
	
  
	
  
	
  
Inauguraldissertation	
  
	
  
	
  
zur	
  
	
  Erlangung	
  der	
  Würde	
  eines	
  Doktors	
  der	
  Philosophie	
  	
  
vorgelegt	
  der	
  
	
  Philosophisch-­‐Naturwissenschaftlichen	
  Fakultät	
  	
  
der	
  Universität	
  Basel	
  
	
  
von	
  
	
  
Kapil	
  Dev	
  Kampe	
  
aus	
  Hyderabad,	
  Indien	
  
Basel,	
  2014	
  
 
	
  
	
  
	
  
	
  
	
  
	
  Genehmigt	
  von	
  der	
  Philosophisch-­‐Naturwissenschaftlichen	
  Fakultät	
  
auf	
  Antrag	
  von	
  
	
  
	
  
Prof.	
  Dr.	
  Ed	
  Palmer	
  
Prof.	
  Dr.	
  Marc	
  Donath	
  
PD	
  Dr.	
  Andreas	
  Jehle	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
Basel,	
  den	
  10.	
  Dezember	
  2013	
  
	
  
	
  
Prof.	
  Dr.	
  Jörg	
  Schibler	
  
Dekan	
  der	
  Philosophisch-­‐
Naturwissenschaftlichen	
  	
  
Fakultät	
  
	
  
	
   I	
  
ABSTRACT	
  
	
  
	
  
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease in 
industrialized countries, and most affected patients have type 2 diabetes. Podocyte injury and 
loss are considered critical in the development, and progression of DN. Several factors of the 
diabetic milieu are well known to impair function and survival of podocytes. However, the 
role of free fatty acids (FFAs), which are elevated in type 2 diabetes, and the role of their 
metabolism are just emerging in the pathogenesis of DN. FFAs were reported to regulate 
podocyte survival. Saturated FFAs, i.e. palmitic acid, were found to induce endoplasmic 
reticulum (ER) stress and podocyte death, whereas monounsaturated FFAs, i.e. palmitoleic 
acid or oleic acid, were protective.  
 
The aims of the present study were to investigate whether FFA metabolism is regulated in 
glomeruli of type 2 diabetic patients with DN and whether regulation of FFA metabolism 
affects the susceptibility of podocytes towards palmitic acid. Particularly, I aimed to 
investigate whether regulation of fatty acid oxidation (FAO) modifies palmitic acid-induced 
podocyte death. As genome wide association studies suggest that acetyl CoA carboxylase 
(ACC) 2, an important enzyme in the regulation of FAO, is involved in the pathogenesis of 
DN, I performed detailed studies investigating the role of ACCs in podocytes. Furthermore, I 
explored the effect of palmitic acid on podocytes in combination with well-known 
proapoptotic stimuli of the diabetic milieu. 
 
The present study uncovered that palmitic acid can aggravate the toxicity of other factors 
which are known to be important in the pathogenesis of DN and which are considered to 
cause podocyte loss. In particular the toxicity of high glucose concentrations and transforming 
growth factor (TGF)-β are substantially increased by palmitic acid, whereas the effect of 
palmitic acid on tumor necrosis factor (TNF)-α induced podocyte death is discret. 
 
In the main part of this study FFA metabolism and its effect on palmitic acid induced 
podocyte death was investigated. The study finds that in glomeruli of type 2 diabetic patients 
mRNA expression levels of several key enzymes involved in fatty acid metabolism are 
altered. Of particular relevance for my detailed studies on FAO, a significant upregulation of 
all three isoforms of carnitine palmitoyltransferase (CPT)-1, the rate-limiting enzyme for 
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FAO, and a downregulation of ACC-2, which catalyzes the formation of the CPT-1 inhibitor 
malonyl-CoA, are found which suggest a disposition for increased FAO. In vitro, stimulation 
of FAO by aminoimidazole-4-carboxamide-1β-D-ribofuranoside (Aicar) or by adiponectin, 
activators of the low-energy sensor AMP-activated protein kinase (AMPK), protect from 
palmitic acid induced podocyte death. Conversely, inhibition of CPT-1, a downstream target 
of AMPK, by etomoxir augments palmitic acid toxicity and impedes the protective Aicar 
effect. Etomoxir blocked the Aicar induced FAO measured with tritium labeled palmitic acid. 
Of note, only double knockdown of ACC1 and ACC2 has a protective effect on palmitic acid 
induced cell death, which indicates that both isoforms contribute to the regulation of FAO in 
podocytes. Furthermore, the effect of Aicar is associated with a reduction of ER-stress as 
indicated by a significant attenuation of the palmitic acid induced upregulation of 
immunoglobulin heavy chain binding protein (BiP), an ER chaperone, and of the proapoptotic 
transcription factor C/EBP homologous protein (CHOP). 
 
In conclusion, palmitic acid increases the toxicity of other factors known to contribute to 
podocyte loss, which underlines the potentially important contribution of elevated saturated 
FFAs in the pathogenesis of DN. An important role of FFAs and of their metabolism in the 
pathogenesis of DN is further suggested by profound changes in gene expression levels of key 
enzymes of FFA metabolism in glomerular extracts of type 2 diabetic patients. The changed 
expression profile indicates a compensatory, protective response. Moreover, the results of this 
study uncover that stimulation of FAO by modulating the AMPK-ACC-CPT-1 pathway 
protects from palmitic acid induced podocyte death. The results of this study should 
encourage further investigations to evaluate the therapeutic potential of interfering with FFA 
metabolism  specifically with stimulating FAO  for the prevention and therapy of DN. 
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1. INTRODUCTION 
 
In the following I will give an introduction into diabetic nephropathy (DN). Thereby, the main 
focus will lie on podocytes which are highly specialized epithelial cells of the glomerular 
filtration barrier and which are thought to be critically involved in the pathogenesis of DN. In 
the second part I will introduce the term “lipotoxicity” and its potential relevance in the 
pathogenesis of DN. As saturated and monounsaturated free fatty acids critically determine 
lipotoxicity, I will review the literature with a special focus on their cellular effects and the 
mechanisms involved herein. Lastly, I will summarize two recent studies related to free fatty 
acids (FFAs) and FFAs metabolism in podocytes in which I have been involved as a coauthor 
and which are directly linked to my main PhD thesis project on fatty acid oxidation and acetyl 
CoA carboxylases (ACCs) in podocytes.   
1.1. Diabetic Nephropathy 
1.1.1. Incidence and prevalence of DN 
  
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD) in 
industrialized countries, e.g. over 40% in the US (Figure 1) (USRDS Annual report, (2013)). 
The majority of diabetic patients starting renal replacement therapy today have type II 
diabetes as the prevalence of type II diabetes is much higher. Of the patients with type II 
diabetes 20-40% develop ESRD (Foley et al., 1998). The five-year survival rate of patients 
with DN and renal replacement therapy is significantly worse than in patients with other renal 
diseases mainly as a result of an increased cardiovascular mortality (Locatelli et al., 2004; 
USRDS, 2011). Therefore, it is important to better understand the pathogenesis of DN, to 
identify new strategies and additional therapeutic targets for the prevention and treatment of 
DN. 
 
 
 
 
 
 
 
Figure 1: Prevalence of ESRD by primary diagnosis (U.S. Renal Data System, USRDS 2013 Annual Data 
Report, Chapter One, Figure 1-15, Volume Two) 
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1.1.2. Pathophysiology of  DN 
 
Dating back to the first description by Kimmelstiel and Wilson (Kimmelstiel P, 1936) the 
typical lesion of DN is mesangial matrix expansion accompanied by hypertrophy of 
mesangial cells, and thickening of the glomerular basement membrane (GBM).  In addition, 
already in these seminal reports intraglomerular lipid deposits were described. 
The classical, earliest clinical sign of DN is microalbuminuria, i. e. loss of small amount of 
albumin in the urine, resulting from damage to the glomerular filtration barrier.  
Consequently, attention to mechanisms focusing on alterations of the glomerular filtration 
barrier seems most warranted.  
The glomerular filtration barrier is made of three interdependent layers (Figure 2), which are 
fenestrated endothelial cells, the GBM, and very specialized epithelial cells, the so called 
podocytes (Figure 2). All these layers form a size- and charge selective renal filtration sieve to 
prevent albumin and other molecules to be lost in the urine.  
 
	
   	
  
 
Figure 2: Structure of the glomerular filtration barrier. A) Schematic picture of the glomerular filtration barrier 
consisting of fenestrated endothelium cells, the glomerular basement membrane (GBM), and podocytes with 
their interdigitating foot process (Image from: J Patrakkaa and K Tryggvasona. Biochem Biophys Res Comm., 
2010 (Patrakka and Tryggvason, 2010)); B) Image taken using a scanning electron microscope of a podocyte 
wrapped around a glomerular capillary (Image from: Smoyer WE & Mundel P, J Mol Med, 1998 (Smoyer and 
Mundel, 1998)). 
	
  
1.1.3. The role of podocytes in the pathogenesis of DN 
	
  
Over the past two decades by elucidating the genetic origin of a number of single human gene 
defects that result in congenital or early onset focal segmental glomerulosclerosis with 
massive proteinuria, it has become apparent that podocytes are the primary affected cell and 
critically determine the proper function of the glomerular filtration barrier (Kriz, 2003; Reidy 
and Kaskel, 2007). Also, in many other renal diseases with proteinuria including DN 
A	
   B	
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increasing evidence suggests that podocyte dysfunction and loss mainly contribute to the 
development of proteinuria (Jefferson et al., 2008; Shankland, 2006). Podocytes are pericyte-
like cells. They have a complex cellular architecture that includes a cell body, primary 
processes that further ramify into fine secondary foot processes. Individual foot processes 
interdigitate with foot processes of neighboring cells, and the filtration slits between the 
processes are bridged by slit diaphragms, which critically contribute to the selective 
permeability of the glomerular filtration barrier (Mundel and Kriz, 1995; Reiser et al., 2000).  
Moreover, podocytes critically determine the biophysical characteristics of the GBM and they 
are important to counteract the hydrostatic pressure from the glomerular capillaries (Endlich 
and Endlich, 2006). 
 
Podocytopathy in DN is characterized by foot process widening. Importanly, this 
morphological change correlates in type I diabetic subjects with the urinary albumin excretion 
rate (Berg et al., 1998). Both, in patients with type I or type II diabetes the number and 
density of podocytes have been reported to be decreased (Dalla Vestra et al., 2003; 
Pagtalunan et al., 1997; Steffes et al., 2001; White and Bilous, 2000; White et al., 2002), and 
this podocyte loss relates to proteinuria (White and Bilous, 2004). A study performed in Pima 
Indians with type II diabetes suggests that a reduced number of podocytes per glomerulus 
predicts progressive kidney disease (Meyer et al., 1999).  
 
Podocytes have no or very limited ability to replicate (Marshall and Shankland, 2006), 
therefore podocyte death and/or podocyte detachment from the GBM are thought to account 
for podocyte loss. Indeed, podocyturia has been documented in patients with type II diabetes 
and seems to correlate with disease progression (Nakamura et al., 2000).  
	
  
1.1.4. Factors contributing to apoptosis of podocytes in DN 
	
  
It is likely that multiple hits are necessary for the occurrence of injury and ultimately 
apoptosis in podocytes during the development of diabetic nephropathy.  
 
In vitro, high glucose levels induce apoptosis in podocytes, and increased ROS have been 
shown to be important mediators of glucotoxicity (Susztak et al., 2006). In db/db mice 
chronic inhibition of NADPH oxidase was able to reduce podocyte apoptosis and ameliorated 
podocyte depletion, urinary albumin excretion, and mesangial expansion (Susztak et al., 
2006). Of note, increased ROS levels in diabetes do not result from hyperglycemia alone, but 
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angiotensin II (Haugen et al., 2000) as well as elevated free fatty acids (Piro et al., 2002)) may 
also be important contributors.  
 
TGF-β1 mRNA and protein levels are increased in various models of diabetes in rodents, and 
TGF-β signaling can be activated by a large number of mediators in diabetes including ROS, 
angiotensin II, and advanced glycation products (Ziyadeh, 2004). In vitro, TGF-β has been 
reported to induce apoptosis in murine podocyte (Schiffer et al., 2001). In podocytes derived 
from glomeruli of rats angiotensin II was shown to have a pro-apoptotic effect also (Ding et 
al., 2002). Interestingly, this effect was shown to depend on angiotensin II induced TGF-β 
production and could be attenuated by anti- TGF-β antibodies. Most importantly, in db/db 
mice administration of a neutralizing anti-TGF-β antibody was found to prevent the 
mesangial matrix expansion and to protect from a decline in kidney function (Ziyadeh et al., 
2000). Also, tumor necrosis factor (TNF)-α was reported to induce podocyte death (Ryu et 
al., 2012; Tejada et al., 2008), and a variety of direct and indirect evidence suggests that TNF-
α plays an important role in the pathogenesis of DN (Navarro-Gonzalez et al., 2009). 
 
1.2. Lipotoxicity  
 
Obesity, the metabolic syndrome, and type 2 diabetes are associated with elevated serum 
triglycerides and free fatty acids (FFAs). This leads to lipid accumulation in nonadipose 
tissues, including pancreas, heart, liver, and kidneys. Accumulation of excess lipids in these 
organs causes cell dysfunction and cell death. This process is termed lipotoxicity (Brookheart 
et al., 2009).  
 
1.2.1. Lipotoxicity in Diabetic Nephropathy 
	
  
In the kidneys of diabetic humans, intraglomerular lipid deposits were described first in 1936 
by Kimmelstiel and Wilson and subsequently observed by other researchers (Kimmelstiel and 
Wilson, 1936; Lee et al., 1991). Upregulated lipogenic genes and development of glomerular 
and tubular lipid deposits have been observed in different animal models of obesity and 
diabetes mellitus (mice fed high-fat diets, leptin impaired db/db and ob/ob mice, 
streptozotocin-treated rats) (Jiang et al., 2007; Kume et al., 2007; Sun et al., 2002; Wang et 
al., 2005). 
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Importantly, recent data from genome wide association studies (GWAS) suggest a potentially 
important role of FFA metabolism in the pathogenesis of DN. In detail, two GWAS in type 2 
diabetic patients found a polymorphism in a noncoding region of acetyl-CoA carboxylase 
(ACC) 2 with a strong association with proteinuria (Maeda et al., 2010; Tang et al., 2010). 
ACCs catalyze the carboxylation of acetyl-CoA to produce malonyl-CoA, which inhibits 
CPT-1, the rate limiting enzyme of FAO (Figure 3). As the DN-risk SNP of ACC2 results in a 
higher ACC2 expression (Maeda et al., 2010), it can be postulated that this leads to increase 
in malonyl-CoA levels and increased inhibition of CPT-1 with subsequent impairment of  
FAO.  
 
Figure 3: ACC2 inhibits CPT-1 by the production of malonyl-CoA from acetyl-CoA 
 
1.2.2. Lipotoxicity: The role of free fatty acids 
	
  
Elevated FFAs and disturbed FFA metabolism are critical determinants of lipotoxicity 
(Brookheart et al., 2009).  Toxicity has been attributed mainly to saturated fatty acids (SFAs) 
whereas monounsaturated fatty acids (MUFAs) exert beneficial and cytoprotective effects 
(Brookheart et al., 2009; Nolan and Larter, 2009). Up to 80% of the plasma FFAs consist of 
the saturated palmitic (C16:0) and stearic acid (C18:0) as well as the monounsaturated oleic 
acid (C18:1) (Hagenfeldt et al., 1972). 
 
1.2.2.1. The	
  toxicity	
  of	
  saturated	
  free	
  fatty	
  acids	
  
	
  
The toxicity of SFAs has been attributed to multiple cellular mechanisms. One mechanism is 
related to decreased triglyceride (TG) synthesis and accumulation of cytotoxic metabolites 
such as diacylglycerides (DAGs). Of note, MUFAs can induce fatty acid oxidation and 
increase lipid storage in form of TGs, thereby reducing cytotoxic metabolites such as DAGs 
(Nolan and Larter, 2009), and DAG-mediated lipotoxicity may depend on the saturation of 
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fatty acids incorporated in DAGs (Bergman et al.), i. e. DAG with a higher content of MUFAs 
are less toxic.  A second mechanism is related to ceramide synthesis. Palmitic acid is a 
substrate for the production of ceramide (Listenberger and Schaffer, 2002).  Ceramide is a 
lipid secondary messenger involved in initiation of apoptosis. Mechanistically, ceramide 
induces insulin resistance and thereby may affect the prosurvival effect of insulin signaling; 
also, ceramide induces apoptotic pathways via increased membrane permeability of 
mitochondria (Bikman and Summers, 2011; Siskind, 2005). Inhibition of ceramide synthesis 
prevents lipotoxicity in pancreatic β-cells but not fibroblasts, suggesting that cell type-specific 
metabolic channeling of FFAs may be important (Brookheart et al., 2009). In cardiomyocytes, 
palmitic acid leads to depletion of cardiolipin, a phospholipid localized to the inner 
mitochondrial membrane and important for optimal mitochondrial function (Chicco and 
Sparagna, 2007), and  reduced cardiolipin levels are thought to contribute to disruption of the 
mitochondrial inner membrane with release of cytochrome c. (Ostrander et al., 2001). SFAs 
as palmitic acid also effect other mitochondrial membrane phospholipids and thereby disturb 
mitochondrial function and lead to increase production of ROS (Brookheart et al., 2009). 
Importantly, oxidative stress can impair membrane integrity, organelle function, and gene 
expression, and thereby contributing to cell death. A third mechanism linked to the toxicity of 
SFA is related to the endoplasmic reticulum (ER). Palmitic acid rapidly increases the 
saturated lipid content of the ER leading to compromised ER morphology and integrity 
(Borradaile et al., 2006). In pancreatic β-cells palmitic acid depletes ER Ca2+ and slows ER 
Ca2+ uptake (Cunha et al., 2008). Disturbed ER homeostasis with the accumulation of mis- or 
un-folded proteins referred to as ER-stress (Rasheva and Domingos, 2009). ER-stress results 
in several signaling pathways, collectively known as unfolded protein response (UPR). The 
UPR cascade involves three signaling branches that are mediated by ER transmembrane 
receptors: double-stranded DNA-dependent protein kinase (PKR)-like ER kinase (PERK), 
inositol-requiring enzyme 1 (IRE-1), and activating transcription factor 6 (ATF6) (Figure 4). 
These  receptors are bound by the ER chaperone immunoglobulin heavy chain binding protein 
(BiP, also termed GRP78 or HSPA5) that keeps them silenced. Accumulation of unfolded 
and/or misfolded proteins is leading to dissociation of BiP and therefore to the activation of 
PERK, IRE-1 and ATF6. The UPR is primarily an adaptive response to maintain and restore 
proper ER function (Kaufman, 2002; Ma and Hendershot, 2001). However, the UPR is also 
linked to inflammatory signals (Figure 4), which themselves can trigger or maintain ER-
stress. In addition, ER-stress leads to insulin resistance, at least in part through serine 
phosphorylation of insulin receptor substrate 1 (IRS1) by IRE1-activated JNK1 (Figure. 4) 
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(Ozcan et al., 2004). Unresolved and severe ER-stress may lead to apoptosis through up-
regulation of the proapoptotic transcription factor CHOP (also known as DDIT3) (Zinszner et 
al., 1998), and loss of CHOP protects  β cells from apoptosis in the db/db mouse model (Song 
et al., 2008). Conversely, overexpression of BiP in pancreatic beta-cells can reduce palmitic 
acid induced apoptosis (Laybutt et al., 2007) which may be explained by the ability of BiP to 
bind to and thereby repress the activity of the ER-stress transducers (Bertolotti et al., 2000) 
(Figure 4). 
 
 
 
Figure 4: ER-stress and the unfolded protein response (UPR).  In eukaryotic cells monitoring of the ER lumen is 
mediated by three ER membrane-associated proteins , PERK (PKR-like eukaryotic initiation factor 2α kinase), 
IRE1 (inositol requiring enzyme 1), and ATF6 (activating transcription factor-6). In a well-functioning and 
“stress-free” ER, these three transmembrane proteins are bound by a chaperone, BiP/GRP78, in their 
intralumenal domains and rendered inactive. Accumulation of improperly folded proteins and increased protein 
cargo in the ER results in the recruitment of BiP away from these UPR sensors. This results in oligomerization 
and activation of the two kinases,  PERK and IRE1. Activation of the third branch of the UPR requires 
translocation of ATF6 to the Golgi apparatus where it is processed to an active transcription factor. The 
endoribonuclease activity of IRE1α cleaves the mRNA of the X-box binding protein-1 (XBP1), creating an 
active (spliced) form of the transcription factor (XBP1s). XBP1s, alone or in conjunction with ATF6α, launches 
a transcriptional program to produce chaperones (e.g. BiP) and proteins involved in ER-associated protein 
degradation (ERAD). ATF6 regulates XBP1 mRNA expression, and in addition ATF6 regulates together with 
XBP1s the expression of ER chaperones and UPR quality control genes. PERK activation results in 
phosphorylation of eIF2α (eukaryotic translational initiation factor 2α), which converts eIF2α to a competitor of 
eIF2B resulting in reduced global protein synthesis and a subsequent reduction in the workload of the ER. All 
three branches of the UPR are involved in the regulation/activation of the NF-κB-IKK pathway leading to an 
inflammatory response. If the ER-stress is prolonged, the UPR can induce apoptosis involving PERK mediated 
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activation of ATF4, which induces genes involved in apoptosis, e.g. C/EBP homologous protein (CHOP). 
(Adapted from (Hotamisligil, 2010)) 
	
  
1.2.2.2. Modulating pathways and the role of monounsaturated free fatty acids 
 
In contrast to SFAs, monounsaturated fatty acids (MUFAs) exert mainly cytoprotective 
effects (Brookheart et al., 2009; Nolan and Larter, 2009). MUFAs are more potent ligands of 
the peroxisome proliferator-activated receptor α (PPARα), a transcription factor regulating 
lipid metabolism (Keller et al., 1993). PPARα is inducing transcription of genes involved in 
mitochondrial ß-oxidation (Hihi et al., 2002), and increasing ß-oxidation is thought to be a 
mechanism to detoxify cells from SFAs. In addition, MUFAs favor the incorporation of SFAs 
in TG, and this is thought to be cytoprotective as palmitic acid and its metabolites 
incorporated in TG are thought to be “biologicaly inert”, i. e. they are stored away in “safe 
lipid pools” (Nolan and Larter, 2009).  Mechanistically, incorporation of SFA-derived acyl-
CoAs has been suggested to be more efficient in the presence of MUFAs as MUFAs are the 
preferred substrates for acyl-CoA:diacylglycerolacyltransferases (DGATs), that transfer acyl-
CoAs to DAGs to form TGs (Cases et al., 1998; Cases et al., 2001; Hardy et al., 2003; Ricchi 
et al., 2009). Similarly, overexpression of stearoyl-CoA desaturases (SCDs) that desaturate 
saturated FFAs to form MUFAs has been shown to result in resistance to palmitic acid 
induced cell death (Listenberger et al., 2003). Furthermore and as previously discussed, ER-
stress plays an important role in lipotoxicity. Importantly, MUFAs are directly linked to 
attenuation of ER-stress (Diakogiannaki et al., 2008; Holzer et al., 2011).  
	
  
1.2.3. Free fatty acids and their metabolism in podocytes   
	
  
In the following I will summarize recent studies, which are closely linked, to my own PhD 
project and in which I was able to contribute as a coauthor. Also, I will introduce in more 
detail the role of fatty acid oxidation and its regulation by ACCs. 
 
1.2.3.1. Regulation of podocyte survival by free fatty acids 
	
  
Only recently the effect FFAs has been investigated in podocytes. For these studies our 
laboratory used conditionally immortalized mouse podocytes, a well-established model to 
study podocyte biology in vitro (Mundel et al., 1997). As shown in figure 5 palmitic acid dose 
dependently increased both apoptosis and necrosis in podocytes. Podocyte cell death was 
assessed by flow cytometry after staining with Annexin V and propidium iodide (PI). 
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Annexin V-positive/PI-negative podocytes were considered apoptotic, whereas annexin V-
positive/PI-positive podocytes were considered (late apoptotic) necrotic cells .  
  
Figure 5: Palmitic acid induces apoptosis and necrosis of podocytes in a dose-dependent manner. Podocytes 
were exposed to palmitic acid (125 – 500 µM) or BSA (at a concentration quivalent to cells treated with 500 µM 
palmitic acid complexed to BSA) for 38 h. Quantitative analysis of palmitic acid induced podocyte cell death. 
Bar graph represents the mean percentages +/- SD of annexin V-positive/PI-negative (early apoptotic) or 
annexin V-positive/PI-positive (late apoptotic/necrotic)  podocytes (n=3; * p<0.05, ** p < 0.01).(Sieber et al., 
2010) 
 
Similar to other cell type (Guo et al., 2007; Kharroubi et al., 2004; Martinez et al., 2008; Wei 
et al., 2009; Wei et al., 2006) we observed that palmitic acid dose- and time-dependently 
results in ER-stress as indicated by the induction of the proapoptotic transcription factor 
CHOP, which is typically upregulated during severe ER-stress (Zinszner et al., 1998) (figure 
6), (Sieber et al., 2010). 
 
Figure 6: Dose-and time-dependent induction of CHOP in podocytes by palmitic acid ( 
 
Importantly, further experiments demonstrated that palmitic acid induced podocyte death as 
well as ER-stress can be prevented by coincubation with palmitoleic or oleic acid (Sieber et 
al., 2010). Finally, we were able to demonstrate that palmitic acid induced cell death at least 
in part is mediated by CHOP as knockdown of CHOP led to a significantly reduction of 
podocyte death (Sieber et al., 2010). In addition, we and other observed that palmitic acid 
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leads to insulin resistance in podocytes (Sieber and Kampe, unpublished observation, and 
(Lennon et al., 2009)). As insulin signaling has a strong prosurvival effect in many cell types 
(Huber et al., 2003) this may further increase the susceptibility of podocyte to proapoptotic 
stimuli such as palmitic acid.  
 
1.2.3.2. Susceptibility of Podocytes to Palmitic Acid Is Regulated by Stearoyl-CoA 
Desaturases 1 and 2 
 
To study the impact of type 2 diabetes and diabetic nephropathy (DN) on glomerular fatty 
acid metabolism microarray analysis of key enzymes involved in fatty acid metabolism was 
performed. Specifically, our laboratory investigated the gene expression in glomeruli of 
patients with type 2 diabetes mellitus compared to pretransplantation living donors (Sieber et 
al., 2013). Interestingly, the most prominent change was the upregulation of stearoyl-CoA 
desaturases (SCD)-1, and by immunohistochemistry the increased signal for SCD-1 could be 
predominantly observed in podocytes (Sieber et al., 2013). To address the potential 
contributory role of FFAs to the altered gene expression profile in glomeruli and podocytes of 
patients with DN, cultured podocytes were treated with 200µM palmitic acid complexed to 
BSA, compared to uncomplexed BSA, and significantly increased expression of Scd-1 (1.7 ± 
0.7-fold) and Scd-2 (1.9 ± 0.6-fold), the most abundant SCD isoforms in murine kidneys 
(Ntambi and Miyazaki, 2003) and murine podocytes was observed. Further experiments with 
pharmacological and genetic overexpression of SCDs as well as gene silencing of SCD-1, and 
-2 elegantly demonstrated that both isoforms are protective for palmitic acid induced 
podocyte death Figure 7, (Sieber et al., 2013).  
 
Figure 7: Overexpressing SCD-1 partially protects from palmitic acid-induced apoptosis. Podocytes with  SCD-
1 overexpressing were compared to  podocytes with overexpression of GFP. SCD-1 reduced palmitic acid-
induced apoptosis and necrosis in podocytes compared to GFP controls. Bar graph shows mean percentages ± 
SD of apoptotic and necrotic cells after exposure to 200µM palmitic acid for 48 h (n = 3, * p < 0.05, ** p < 0.01, 
(Sieber et al., 2010) 
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Mechanistically, MUFAs or stimulation of SCDs, which convert saturated FFAs to MUFAs, 
promote the incorporation of palmitic acid into TG, suggesting that the protective effect at 
least in part results from compartmentalization of palmitic acid in “safe lipid pools” (Sieber et 
al., 2013). 
 
1.2.3.3. Lipotoxicity: Modulation by fatty acid oxidation and the role of ACCs 
 
Studies in endothelial cells suggest that stimulation of fatty acid oxidation (FAO) protects 
from palmitic acid induced cell death (Borradaile et al., 2006). In these studies FAO was 
stimulated by the by the AMPK agonist aminoimidazole-4-carboxamide-1β-D-ribofuranoside 
(Aicar) which leads to phosphorylation of ACCs resulting in lower malonyl-CoA levels and 
disinhibtion of CPT-1 (Fig. 9), the rate-limiting enzyme of FAO (Muoio and Newgard, 2008). 
 
 
Figure 8: Aicar stimulates fatty acid oxidation. Figure depicts the metabolic pathway activated by Aicar, which 
results in stimulation of fatty acid oxidation. 
 
As mentioned above (section 1.2.1.), two recent GWAS in type 2 diabetic patients found a 
polymorphism in a noncoding region of ACC2 with a strong association with proteinuria 
(Maeda et al., 2010; Tang et al., 2010). The DN-risk single nucleotide polymorphism of 
ACC2 results in a higher ACC2 expression (Maeda et al., 2010) potentially leading to 
increased malonyl-CoA levels and decreased FAO. 
 
In humans and rodents there are two ACC isoforms, ACC1 (ACC alpha) and ACC2 (ACC 
beta) (Savage et al., 2006), which share considerable sequence identity and the same domain 
structure responsible for enzyme activity (Savage et al., 2006). In contrast to ACC1, ACC2 
has an extra N-terminal hydrophobic domain, which facilitates its localization to the 
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mitochondrial membrane (Abu-Elheiga et al., 2005), where it preferentially regulates local 
malonyl-CoA levels and CPT-1 activity. In contrast cytosolic ACC1 is classically thought to 
regulate malonyl-CoA synthesis for incorporation into fatty acids in lipogenic tissues. 
However, more recently this classical view has been challenged, and at least in some cell 
types, e.g. hepatocytes, both isoforms have been shown to regulate CPT-1 activity 
synergistically (Savage et al., 2006).  
  
	
   13	
  
1.3. Aim of the study 
 
Increasing evidence suggests that damage and loss of podocytes are early events in DN and 
critically determine disease progression. Several factors of the diabetic milieu are known to 
impair function and survival of podocytes. Although lipid accumulation is a well known 
feature of DN, only recently the potentially important role of FFAs and FFA metabolism in 
this process were acknowledged. 
Over the last five years our laboratory systematically analyzed the effects of FFAs as well as 
FFA metabolism in podocytes. A key finding was that FFAs can regulate podocyte survival. 
Specifically, SFAs, i.e. palmitic acid, were found to induce endoplasmic reticulum (ER) stress 
and podocyte death, whereas monounsaturated FFAs, i.e. palmitoleic acid or oleic acid, were 
protective. 
The aims of the present study were to investigate whether FFA metabolism is regulated in 
glomeruli of type 2 diabetic patients with DN and whether regulation of their metabolism 
affects the susceptibility of podocyte towards palmitic acid. The main focus was to understand 
whether regulation of FAO modifies palmitic acid-induced podocyte death. As genome wide 
association studies suggest that acetyl CoA carboxylase (ACC) 2, an important enzyme in the 
regulation of FAO, is involved in the pathogenesis of DN, detailed studies investigated the 
role of ACCs in podocytes. Furthermore, I investigated whether palmitic acid modifies 
podocyte death induced by other factors of the diabetic milieu, which have been shown to be 
involved in the pathogenesis of DN and which are thought to contribute to damage and loss of 
podocytes. 
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2. MATERIALS AND METHODS 
 
2.1. Cell culture 
 
Podocytes were cultured following the protocol described by Mundel et al (Shankland et al., 
2007). Conditionally immortalized mouse podocyte cell lines were established from the 
immortomouse, which carries a thermosensitive (ts58A) variant of the SV 40 T antigen as a 
transgene (Shankland et al., 2007). Podocytes having the passage number from 4 to 14 are 
utilized for performing the experiments. First, podocytes were cultured or proliferated in 
permissive conditions which include growing in 33°C with 50U/ml interferon gamma (IFN-γ, 
# CTK-358-2PS, MoBiTec GmbH, Germany) for first two passages, later IFN-γ concentration 
can be brought down to 10U/ml. Differentiation of podocytes is done in non-permissive 
conditions which includes thermoshift to 37°C without IFN-γ. Podocytes were allowed to 
undergo differentiation atleast 11 days prior to the start of experiments.  
 
Podocytes are cultured in RPMI-1640 (#21875, Invitrogen) supplemented with 10% FBS 
(#10270, Invitrogen), 100 U/ml penicillin and 100 µg/ml streptomycin (#15140, Invitrogen). 
For apoptosis experiments, β-oxidation experiments 6-well plates were employed and for 
isolating mRNA and protein 10-cm dishes were employed from BD biosciences. All the 
plates and dishes were coated with 0.1 mg/ml type I collagen (BD biosciences) prior to 
seeding the cells. Freezing of the cells was performed in complete culture medium 
supplemented with 8% (v/v) dimethylsulfoxide (Sigma). For the production of lentiviral 
particles, HEK293 cells were employed as packaging cells. HEK293 cells were cultured in 
DMEM (#41965, Invitrogen) supplemented with 10% FBS and penicillin/streptomycin. 
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2.2. Agonists, inhibitors and cytokines 
 
Substance Supplier (catalog number) Physiological role Concentration applied 
Aicar Cell signaling (#9944) AMPK agonist 0.5mM 
Adiponectin BioVision (#4902-100) AMPK agonist 0.5µg/ml 
Compound C Sigma (#5499) AMPK inhibitor 4µM 
Etomoxir Sigma (#E1905) CPT-1 inhibitor 10, 30 and 200µM 
TGFβ Roche (#10874800)  5ng/ml 
TNFα Sigma (#T7539)  5ng/ml 
 Table 1: Agonists, inhibitors and cytokines 
 
2.3. Free fatty acids preparation 
 
Sodium palmitate and oleic acid (both from Sigma) were dissolved overnight at 10 mM in 
glucose-free RPMI-1640 medium (#11879) containing 11% essential fatty-acid free BSA 
(Sigma) under N2-atmosphere at 55°C, sonicated for 10 min and sterile filtered (stock 
solution). The molar ratio of fatty acid to BSA was 6:1.The effective free fatty acid 
concentrations were measured with a commercially available kit (Wako). Endotoxin 
concentration was equal or less than 0.5ng/ml, as determined by a kit (#L00350) from 
Genscript (Piscataway, NJ, USA). 
 
2.4. Apoptosis assay 
 
The cells were trypsinized, washed once with PBS, and resuspended in 120 µl annexin V 
binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). 100 µl of the cell 
suspension was used for the staining procedure. Alexa-647 annexin V (#A23204, Invitrogen) 
staining was applied for 15 min at room temperature at a dilution of 1:100 (see producer 
protocol) and before analyzing an additional 400 µl of annexin V binding buffer was added 
along with 0.5µg propidium iodide (#P3566, Invitrogen) were added. 20’000 – 25’000 cells 
were analyzed by flow cytometery with CyAn™ ADP Analyzer (Beckman Coulter). Data 
from flow cytometry was analyzed by FLOWJO (Tree Star, Inc. Ashland, OR, USA) software 
program. Annexin V-positive/PI-negative podocytes were considered apoptotic, whereas 
annexin V-positive/PI-positive podocytes were considered (late apoptotic) necrotic cells.  
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2.5. ACC1 and ACC2 knock down 
 
2.5.1. shRNA sequences and lentiviral expression vector 
 
For the knock down, ACC1, ACC2 and scrambled shRNA sequences were cloned into pSIH-
H1-puro lentiviral expression plasmid, which is a kind gift of Dr. Markus Heim, (University 
Hospital Basel, Switzerland). Respective details of shRNA sequences are furnished in table 1 
along with information of plasmids and references. pSIH-H1-puro was first linearized with 
EcoR1/BamH1 restriction enzymes and at the same time shRNA oligos of respective genes 
were designed and ordered with restriction sites for EcoR1/BamH1 flanking them to facilitate 
cloning into the pSIH-H1-puro vector. Next, shRNA oligos were ligated with digested pSIH-
H1-puro and ligation product was transformed into competent E.coli strain, DH5-α. 
Following day of bacterial transformation, colonies were randomly picked and miniprep was 
done to isolate plasmid and which further sent to sequencing for confirmation.  
 
Gene shRNA sequence (5’ – 3’) Vector GeneBank 
number 
Reference 
ACC1 GCAGATTGCCAACATCCTAGA pSIH-H1-puro NM_133360 (Jeon et al., 2012) 
ACC2 GTGGTGACGGGACGAGCAA pSIH-H1-puro NM_133904 (Jeon et al., 2012) 
ACC2 (2) GAGGTTCCAGATGCTAATG pSIH-H1-puro NM_133904 Optimized 
Scrambled  GACCGCGACTCGCCGTCTGCG pSIH-H1-puro  (Sieber et al., 2010) 
Table 2: shRNA sequences and respective plasmids. 
 
2.5.2. Lentiviral production 
	
  
A 4-plasmid based lentiviral system (kindly provided by Dr. Markus Heim, University 
Hospital Basel, Switzerland) was employed with following helper plasmids: pRSV-REV (Rev 
expression vector), pMDLg/pRRE (Gag-Pol expression vector), and pMD2.G (VSV-G 
expression vector). All helper plasmids along with pSIH-H1-puro were mixed with 45µl of 
FuGene HD (Promega, Madison, WI, USA) transfection agent in total 3ml of Opti-MEM 
(#31985, Gibco) and incubated at room temperature for 20min. Next HEK293 were 
transfected in a 10-cm dish with 5ml of DMEM (#41965) without antibiotics and medium 
was changed after 8-12h, followed by addition of fresh complete 10ml of DMEM (conditions 
for transfection is detailed in table 2). HEK293 cells were grown upto 60 to 70% confluence 
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before transfection. 48h post transfection, the supernatant medium enriched with lentiviral 
particles was harvested, spun at 780g for 5min and filtered through 0.45µm filter.  
 
Transduction of podocytes was done by adding virus containing media with pre-treating 
podocytes with 5µg/ml polybrene (Sigma) for 5min.	
  8-24 hours after transduction, medium 
was exchanged. Experiments were performed three to five days after viral transduction. 
Amount of viral particles to be used for transducing cells was standardized separately by 
employing a GFP-based lentiviral expression plasmid FUGW, which facilitates the visual 
inspection of the efficiency of viral transduction. For all the experiments a viral titer to 
achieve efficiency of 70 – 80% was employed. 
Plasmid/Reagent Amount 
pSIH-H1-puro (with respective shRNA sequence) 9 µg 
Rev expression vector (pRSV-REV) 1.8 µg 
Gag-Pol expression vector (pMDLg/pRRE) 4.5 µg 
VSV-G expression vector (pMD2.G) 2.7 µg 
Total plasmid DNA 18 µg 
FuGene HD 45 µl 
Total Opti-MEM 3 ml 
Table 3: Summary of transfection conditions for the production of lentiviral particles. 
 
2.6. Western Blot 
	
  
For protein isolation cells were always cultured in 10-cm dishes. For isolating protein, 
medium was sucked off and cells were washed with ice cold PBS and scraped in 180 µl RIPA 
lysis buffer (50mM Tris-HCl, pH 7.5, 200 mM NaCl, 1% Triton, 0.25% deoxycholic acid, 1 
mM EDTA, 1mM EGTA) containing EDTA-free protease inhibitors (#11873580001, Roche) 
and phosphatase inhibitors (#78420, Pierce). Then collected cells were lysed mechanically 
and rotated for 1 h at 4°C. To remove nuclei, the samples were spun down (10’000 rpm, 10 
min) and the protein concentration of the supernatant was determined by DC Protein Assay 
(Bio-Rad). 20 - 80 µg of protein was complemented with 6x sample buffer (200 mM Tris-HCl 
pH 6.8, 26% glycerol, 10% SDS, 0.01% bromphenol blue) and DTT (final concentration of 
100 mM) and heated for 10 min at 95°C. Protein samples were loaded on 7-12% gels and 
SDS-PAGE was performed at 150 V. Transfer to nitrocellulose membranes (Protran BA83, 
Whatman Schleicher und Schuell) was applied at 100 V in the cold room for 1 hour and the 
blots were blocked for 2 hours with 5% milk powder in TBS-Tween (50 mM Tris HCl pH 
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7.4, 150 mM NaCl, 0.02% Tween). Primary antibodies were applied overnight and the 
secondary antibodies for 1 hour in 5% milk in TBS-Tween. The immunoblots were detected 
by enhanced chemiluminescence (#34094, Pierce) on Kodak BioMax light films (#Z370398-
50EA, Sigma). The list of primary and secondary antibodies employed with respective 
dilutions is detailed in table 3. 
Antigen Species Conjugate Supplier (catalog number) Dilution 
ACC1/2 Rabbit Purified Cell signaling (#3676) 1:500 
AMPK Rabbit Purified Cell signaling (#2532) 1:1000 
BiP Rabbit Purified Cell signaling (#3177) 1:500 
CHOP Mouse Purified Santa Cruz (#sc-7351) 1:200 
Mouse IgG Rabbit antiserum HRP Dako (#P0260) 1:4000 
pAMPK Rabbit Purified Cell signaling (#2531) 1:200 
pACC Rabbit Purified Cell signaling (#3661) 1:500 
Rabbit IgG Goat antiserum HRP Dako (#P0448) 1:1600 
ß-actin Mouse Purified Sigma (#A5441) 1:50,000 
Table 4: List of primary and secondary antibodies for western blot. 
 
2.7. β-oxidation measurement 
 
For measuring the β-oxidation of palmitic acid, tritium labeled palmitic acid (3H-palmitic 
acid, #NET043001MC Perkin Elmer, Schwerzenbach, Switzerland) was employed. For these 
experiments, Aicar was pre-incubated for 1h if necessary and serum starvation medium was 
employed having 0.2% FBS, 5 mM glucose which is supplemented with 0.5% FFA-free BSA. 
For all the experiments 200µM of palmitic acid and 0.5µCi/ml 3H-palmitic acid was applied. 
After the incubation times of experiment, 1ml of the supernatant medium was taken and 
added to 5ml of chloroform/methanol/5N HCl (2:1:0.05, v/v) and rotated for 5min. Later, the 
mixture was spun down at 350xg for 5 min, which apparently separates upper aqueous and 
lower organic phase. Now 500µl of upper aqueous phase was taken and added to 2ml of 
scintillation liquid (Insta-gel Plus, Packard, Groningen, The Netherlands) in a special 
scintillation reading tubes (Perkin elmer). Tubes were thoroughly mixed before they were put 
in scintillation reader (Packard, Canberra, CT, USA) for measuring radioactivity. β-oxidation 
values were obtained as disintegrations per minute (DPMI) and were normalized to total 
protein. 
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2.8. Statistical analysis 
 
All the experiments were performed at least 4 times and representative result was shown. 
Data are expressed as means ± SD unless otherwise mentioned.  One way ANOVA was 
performed and for calculating significance of differences, Bonferroni post hoc test was 
employed. The prism 6 program was used for the analysis and differences were considered 
significant when P value was < 0.05. 
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3. RESULTS 
 
3.1. Palmitic acid induced podocyte death: Modification by high glucose, 
TGF-β, and TNF-α 
	
  
As reported by us and confirmed in independent studies, podocytes are highly susceptible to 
palmitic acid induced cell death (Sieber et al., 2010) (Sieber et al., 2013; Tao et al., 2012). 
Previously other factors of the diabetic milieu have been reported to induce podocyte death, 
including high glucose concentrations (Susztak et al., 2006), TGF-β (Schiffer et al., 2001), 
and TNF-α (Ryu et al., 2012; Tejada et al., 2008). I explored the effect of these factors in 
combination with palmitic acid in podocytes. 
	
  
3.1.1. Palmitic acid uncovers the toxicity of high glucose concentrations 
	
  
High glucose concentrations (20 – 30 mmolar) have been reported to induce apoptosis in 
podocytes (Susztak et al., 2006). In these studies apoptosis was quantified by assessment of 
nuclear condensation following DAPI staining and by a caspase 3 activity assay (Susztak et 
al., 2006). To see whether high glucose in combination with palmitic acid affects podocyte 
survival, I treated podocytes with normal glucose (NG, 11mM) or high glucose (HG, 22mM) 
in the presence or absence of 200µM palmitic acid for 48h (Figure 9). Podocyte cell death 
was assessed by flow cytometry after staining with Annexin V and propidium iodide (PI). 
Annexin V-positive/PI-negative podocytes were considered apoptotic, whereas annexin V-
positive/PI-positive podocytes were considered (late apoptotic) necrotic cells (Sieber et al., 
2010). As shown in figure 9, high glucose alone had no significant effect on podocyte death in 
the presence of BSA which was used as the appropriate control for podocytes treated with 
palmitic acid complexed to BSA. However, high glucose significantly increased podocyte 
apoptosis in the presence of palmitic acid (155.3 ± 16.8%, p < 0.01). As the toxicity of high 
glucose was only seen in the presence of palmitic acid in these experiments we can also say 
that toxicity of glucose was “uncovered” by palmitic acid.   
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Figure 9: High glucose accentuates the to toxicity caused by palmitic acid in podocytes. Podocytes were 
incubated with either 11mM glucose (NG) or 22mM glucose (HG) in presence of 200µM palmitic acid or BSA 
(control) for 48h. 11mM of mannitol was employed to NG conditions to correct for osmolality. Bar graph 
represents mean percentages ± SD of apoptotic and necrotic cells (n = 3, * *p < 0.01). 
 
3.1.2. TGF-β aggravates palmitic acid induced podocyte death 
	
  
Considerable evidence suggests that TGF-β plays an important role in the pathogenesis of DN 
(Chen et al., 2003), and TGF- β has been reported to induce apoptosis in murine podocyte 
(Schiffer et al., 2001). Therefore podocytes were treated with either 200µM palmitic acid or 
BSA (control) in the presence or absence of 5ng/ml TGF-β for 48h (figure 10). TGF-β could 
accentuate the toxicity caused by palmitic acid, as both apoptosis and necrosis levels were 
increased by 157.4 ± 10.2% (p<0.01) and 145.5 ± 10.6% (p<0.01) respectively. The effect of 
TGF-β alone on podocyte death was minimal and did not reach statistical significance, 
however the toxicity of TGF-β was again uncovered by the co-treatment with palmitic acid.  
 
 
Figure 10: TGF TGFβ increases the toxicity caused by palmitic acid in podocytes: Podocytes were treated either 
with 200µM palmitic acid or BSA (control) with or without 5ng/ml TGFβ for 48h. Bar graph represents mean 
percentages ± SD of apoptotic and necrotic cells (n = 3, * *p < 0.01). 
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3.1.3. TNF alpha aggravates palmitic acid induced podocyte death 
	
  
A variety of direct and indirect evidence suggests that tumor necrosis factor alpha (TNF-α) 
plays a role in the pathogenesis of DN (Navarro-Gonzalez et al., 2009). Also, TNF-α was 
reported to induce podocyte death (Ryu et al., 2012; Tejada et al., 2008). To examine whether 
TNF-α affects palmitic acid induced podocyte death, podocytes were treated with 5ng/ml of 
TNFα alone or in combination with 200µM palmitic acid for 48h (Figure 11). TNF-α 
significantly increased podocyte death, specifically apoptosis was increased by 168.1 ± 20.9% 
(p < 0.01), and necrosis by 120.6 ± 10.2% (p < 0.05). However, the increase of palmitic acid 
induce podocyte death by TNF-α was modest, and only apoptosis was significantly increased 
by 116.0 ± 7.9 (p < 0.05). 
 
 
Figure 11: TNFα induces podocyte death and aggravates palmitic acid induced toxicity. Podocytes were treated 
with either 200 µM BSA or palmitic acid in presence or absence of 5 ng/ml TNFα for 48 h. Bar graph represents 
mean percentages +/- SD of apoptosic necrotic cells (n=3, **p < 0.01, *p < 0.05). 
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3.2. Regulation of fatty acid oxidation in palmitic acid induced podocyte 
cell death: Critical role of Acetyl CoA carboxylase 1 and 2 
3.2.1. Differential regulation of genes involved in fatty acid metabolism in glomeruli  of 
patients with established DN 
 
To see whether enzymes of fatty acid metabolism might be regulated in DN, we performed 
microarray analysis of different enzymes involved in fatty acid metabolism in glomeruli from 
type 2 diabetic patients with DN and compared them to glomeruli from pretransplantation 
living donors (Sieber et al., 2013). Significantly altered expression levels of several enzymes 
involved in FAO and TG synthesis was observed (Figure 12). The most prominent change 
was the induction of SCD-1, which provides DGATs with their preferential substrates, 
MUFAs. Together with the positive regulation of DGAT1, which catalyzes the incorporation 
of exogenous FFAs into TG, this implies a disposition towards increased TG synthesis. 
Furthermore, we saw a significant upregulation of all three isoforms of CPT-1, the rate-
limiting enzyme for fatty acid oxidation, and a downregulation of ACC-2, which catalyzes the 
formation of the CPT-1 inhibitor malonyl-CoA, which suggests a disposition for increased 
fatty acid oxidation.  
 
 
Figure 12: Differential expression of genes related to fatty acid metabolism in glomeruli of DN patients. 
Microarray data were obtained from isolated glomeruli of type 2 diabetic patients with DN and controls 
(pretransplant allograft biopsies). Expression of fatty acid oxidation related genes such as ACC2, CPT-1a, CPT-
1b and CPT-1c, were significantly regulated in DN compared to controls. Up regulated enzymes are indicated in 
red, down regulated enzymes in blue colors. 
	
  
3.2.2. Modulation of fatty acid oxidation and its effect on palmitic acid induced 
podocyte death 
3.2.2.1. AMPK activation protects from palmitic acid induced cytotoxicity 
 
To investigate whether stimulation of fatty acid oxidation (FAO) plays a protective role in 
palmitic acid treated podocytes, we took advantage of the AMP-activated protein kinase 
(AMPK) activator 5-aminoimidazole-4-carboxamide-1β-D-ribofuranoside (Aicar). Aicar (as 
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well as adiponectin (Sharma et al., 2008)) acts by phosphorylating AMPK, which in turn 
phosphorylates and inhibits ACC resulting in disinhibition of CPT-1 (Figure 13). 
 
Figure 13: Scheme representing the metabolic path activated by Aicar and Adiponectin. Aicar and Adiponectin 
activate AMPK by phosphorylation. AMPK phosphorylates and inhibits ACC which results in decreased 
synthesis of malonyl CoA and disinhibition of CPT-1 resulting in upregulation of fatty acid oxidation. 
	
  
In a first step, phosphorylation of AMPK and ACC by Aicar in podocytes was examined by 
Western immunoblotting (Figure 14). 
 
 
Figure 14: Aicar phosphorylates AMPK and ACC. Immunoblot shows phosphorylation of AMPK and ACC 
after incubation of podocytes with either (PBS) vehicle or 0.5 mM Aicar for 14 hours. Total AMPK and total 
ACC served as loading controls. 
 
Functionally, as shown in Figure 15, Aicar significantly prevented palmitic acid induced 
podocyte death assessed by flow cytometry after staining for Annexin V and propidium 
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iodide (PI). Specifically, Aicar reduced palmitic acid induced apoptosis and necrosis by 50.5 
± 1.5% (p < 0.01) and 42.5 ± 6.1% (p < 0.05) respectively. 
 
Figure 15:  Aicar attenuates palmitic acid induced podocyte death. Podocytes were treated with either 200µM 
palmitic acid or BSA (control) with or without 0.5mM Aicar for 48h. Podocytes were preincubated with Aicar 
for 1h. Representative bar graph shows mean percentages ± SD apoptotic and necrotic podocytes. (n=3, *p<0.05, 
**p<0.01) 
Similarly to Aicar, the physiological AMPK agonist adiponectin (Sharma et al., 2008) also 
reduced palmitic acid induced podocyte death, although to a lesser extent than Aicar (figure 
16). Specifically, adiponectin significantly decreased apoptosis by 14.1 ± 4.7% (p < 0.05), but 
the reduction of necrosis by 9.9 ± 6.3% did not reach statistical significance. To see the 
protective effect of adiponectin podocytes were kept at a high glucose concentration of 22 
mmol/L, which is known to reduce phosphorylation of AMPK (Sharma et al., 2008) and 
increases the susceptibility of podocytes to AMPK activation (Sharma et al., 2008).  
 
Figure 16: Adiponectin decreases apoptosis induced by palmitic acid. Podocytes were treated with either 200µM 
palmitic acid or BSA (control) with or without 0.5µg/ml adiponectin for 48h. 22mM of glucose was employed. 
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Podocytes were preincubated with adiponectin for 1h. Bar graph represents mean percentages ± SD of apoptotic 
and necrotic cells (n = 3, ** p < 0.01, * p < 0.05). 
 
3.2.2.2. Inhibition of AMPK exacerbates palmitic acid induced cell death and reversed 
the protection caused by Aicar. 
 
To further to explore the role of AMPK we used the AMPK inhibitor compound C. 
Compound C was used at a low concentration of 4 µM, as higher concentrations were toxic, 
i.e. podocyte death was markedly increased for BSA control (data not shown). The Aicar 
induced ACC phosphorylation was significantly reduced by compound C (Figures 17A, and 
17B, p < 0.05).  
A) 
 
B) 
 
 
In line with the inhibitory effect of compound C on the AMPK-ACC-CPT-1 pathway, 
compound C treatement increased palmitic acid induced apoptosis and necrosis in podocytes 
by 140.1 ± 20.1 % (p < 0.01) and 130.9 ± 14.0% (p < 0.01), respectively. In agreement with 
the partial reduction of the Aicar induced ACC phosphorylation, (Figure 17) cotreatment with 
compound C compared to Aicar alone only moderately increased palmitic acid induced 
podocyte death, i.e. apoptosis was increase by 128.2 ± 9.3 % (NS) and necrosis by 176.7 ± 
9.7% (p < 0.01) (Figure 18). 
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Figure 17: Compound C inhibits Aicar 
induced phosphorylation of ACC. A. 
Podocytes were incubated with DMSO, 
0.5mM Aicar and Aicar in combination of 
4µM of compound C. pACC was 
immunoblotted and total ACC served as 
loading control. B. Quantification of pACC 
by densitometry. Bar graph represents the 
relative expression ± SD (*p < 0.05). 
DMSO treated controls were set to 100%. 
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Figure 18: Compound C accentuates palmitic acid induced podocyte death and partially reverses the protection 
by Aicar. Podocytes were incubated with 200µM palmitic acid or BSA (control) either with or without 4 µM of 
Compound C, or either with 0.5mM Aicar alone or in combination with Compound C for 48h. Bar graph 
represents mean percentages ± SD of apoptotic and necrotic cells (n = 3, **p < 0.01). 
3.2.2.3. Etomoxir aggravates palmitic acid induced podocyte death and reverses the 
protective Aicar effect 
 
To further investigate the impact of FAO on palmitic acid induced podocyte death I made use 
of the CPT-1 inhibitor etomoxir (Figure 19A). Etomoxir exacerbated palmitic acid induced 
podocyte death (Figure 19B). Specifically, apoptosis was increased by 184.3 ± 6.0% (p < 
0.01) and necrosis by 185.1 ± 16.3% (p < 0.01). Moreover, etomoxir reversed the protective 
effect of Aicar (Figure 20). Of note, this effect could already be seen at a very low etomoxir 
concentration (10 µM), which by itself had no significant effect on palmitic acid induced 
podocyte death (data not shown). Compared to podocytes treated with Aicar alone, the 
presence of 10µM etomoxir increased palmitic acid mediated apoptosis by 131.1 ± 5.0% (p < 
0.05) and necrosis by 127.3 ± 10.7% (p < 0.05). At 200 µM, etomoxir completely reversed the 
protective effect of Aicar (Figure 20). 
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Figure 19: Etomoxir exacerbates palmitic acid induced podocyte death. A: Scheme shows mechanism of action 
of etomoxir, a CPT-1 inhibitor, in inhibiting fatty acid oxidation. B: Etomoxir aggravated palmitic acid induced 
cell death after 48h. Podocytes were treated with 200µM palmitic acid or BSA (control) in the presence or 
absence of etomoxir. Bar graph represents mean percentages ± SD of apoptotic and necrotic cells (n = 3, 
**p<0.01).   
 
 
Figure 20: Etomoxir reverses the protection by Aicar for palmitc acid induced podocyte death. Podocytes were 
treated with 200 µM palmitic acid or BSA (control) in the presence or absence of etomoxir (10 µM or 200 µM) 
and/or 0.5 mM Aicar. Bar graph represents mean percentages ± SD of apoptotic and necrotic cells (n = 3, * p < 
0.05, **p < 0.01). 
 
3.2.2.4. Aicar stimulates and etomoxir inhibits fatty acid oxidation 
 
To directly measure the effect of Aicar on palmitic acid oxidation, I treated podocytes with 
200 µM palmitic acid along with 0.5 µCi/ml tritiated palmitic acid in the absence or presence 
of Aicar. As a direct read out of palmitic acid β-oxidation, tritiated water released in the 
supernatants of podocytes was measured. As expected the release of tritiated water gradually 
increased from 1 to 3 hours (Figure 21). The stimulation of podocytes with Aicar significantly 
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increased the formation of tritiated water (146.6 ± 22.0%, p < 0.05, Figure 21) reflecting the 
stimulatory effect of Aicar on palmitic acid oxidation.  
 
 
Importantly, and as shown in Figure 22, the effect of Aicar could be completely prevented by 
etomoxir.  
 
Figure 22: Etomoxir prevents the Aicar induced β-oxidation. Podocytes were treated with 0.5% FFA free-BSA 
with 200 µM palmitic acid supplemented with 0.5 µCi/ml [3H]-palmitic acid either in the presence of 0.5mM 
Aicar alone or in combination with 30 µM etomoxir for 3h. Bar graph represents relative ß-oxidation (%) ± SD 
(n = 3, * p < 0.05) 
 
3.2.2.5. Combined silencing of ACC1 and ACC2 protects from palmitic acid induced 
podocyte death 
	
  
Two recent genome wide association studies (Maeda et al., 2010; Tang et al., 2010) found a 
single nucleotide polymorphism in ACC2, leading to increased ACC2 expression (Maeda et 
al., 2010)  to be associated with proteinuria in type 2 diabetic patients. To investigate further 
the role of both ACC isoforms in podocytes, I generated cells deficient of ACC1, ACC2, or 
both by lentiviral infection using specific short-hairpin (sh) RNAs. Knock down of ACC1 but 
not ACC2 strongly reduced the band corresponding to both isoforms. The residual band seen 
Figure 21: Aicar increased β-oxidation of 
palmitic acid. Podocytes were treated with 
0.5% FFA free-BSA with 200µM palmitic 
acid in presence of 0.5 µCi/ml [3H]-
palmitic acid for indicated time points in 
presence or absence of 0.5mM Aicar. 
Podocytes were preincubated for 1h with 
0.5mM Aicar. Bar graph represents relative 
ß-oxidation ± SD (n = 3, ** p < 0.01). 
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in ACC1 single knock down podocytes was almost completely gone in ACC1/ACC2 double 
knock down cells (Figure 23). These data suggest that the expression level of ACC1 is much 
higher than ACC2 in podocytes.  
 
 
Figure 23: Immunoblot for ACC1, ACC2 and ACC1/2 knock down. ACC1, ACC2 or both were knocked down 
and an immunoblot was done with an antibody recognizing both isoforms. ß-actin served as a loading control. 
 
As shown in Figure 24, single knock down of ACC1 or ACC2 was not able to protect from 
palmitic acid induced podocyte death.  
 
Figure 24: ACC1 or ACC2 single knockdown is not protective for palmtitic acid induced podocyte death. 
Podocytes were silenced with either ACC-1 or ACC-2, and were treated with either 200 µM  palmitic acid or 
BSA (control) for 48h.The bar graph shows mean percentage apoptotic or necrotic cells ± SD (n=3). 
	
  
Contrariwise, double knockdown of both isoforms significantly reduced palmitic acid induced 
podocyte death. Specifically, in ACC1/ACC2 double knockdown podocytes palmitic acid 
induced apoptosis and necrosis was reduced by 59.6 ± 4.5% (p < 0.01) and 64.4 ± 6.4% (p < 
0.01) compared to podocytes transfected with scrambled shRNA (Figure 25).  
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Figure 25: Combined knock down of ACC1 and ACC2 protects podocytes from palmitic acid induced cell 
death. Podocytes were treated either with 200µM palmitic acid or BSA (control) for 48h. The bar graph 
represents % mean apoptotic or necrotic cells ± SD. (n=3, **p<0.01). 
 
To further corroborate these results I used a different set of shRNAs directed against ACC1 
and ACC2. As shown in Figure 26, the protective effect with this second set was similar to 
the first set.  
 
Figure 26: Combined knock down of ACC1 and ACC2 with a second set of shRNAs against ACC1 and ACC2 
protects podocytes from palmitic acid induced cell death. Podocytes were treated either with 200µM palmitic 
acid or BSA (control) for 48h. The bar graphs represent percentages of mean apoptotic or necrotic cells ± SD. (n 
= 3, * p < 0.05, ** p < 0.01).  
	
  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Scram+BSA Scram+palm ACC1/2Kd+BSA ACC1/2Kd+palm 
%
 a
po
pt
ot
ic
/n
ec
ro
tic
 c
el
ls
 
Apoptosis	
  
Necrosis	
  
**	
  
**	
  
0	
  
2	
  
4	
  
6	
  
8	
  
10	
  
12	
  
14	
  
Scram+BSA	
   Scram+Palm	
   Acc1/2Kd+BSA	
   Acc1/2Kd+Palm	
  
%
	
  a
po
pt
oZ
c/
ne
cr
oZ
c	
  
ce
lls
	
   Apoptosis	
  
Necrosis	
  
**	
  
*	
  
	
   32	
  
However, single knock down of ACC1 or ACC2 was again not protective (data not shown). 
In a next step the effect of Aicar was tested in ACC1/ACC2 double silenced podocytes. The 
residual protective effect shown in figure 27 was weak and not consistently seen in all 
experiments performed.   
 
 
Figure 27: Modest effect of Aicar in ACC1/ACC2 double silenced podocytes. ACC1/ACC2 double silenced 
podocytes and scramble controls were treated either with 200 µM palmitic acid or BSA (control) for 48h in 
presence or absence of 0.5 mM Aicar. Bar graph represents  % mean apoptotic or necrotic cells ± SD. (n=3, 
*p<0.05, **p<0.01) 
	
  
3.2.2.6. Aicar reduces ER-stress and the upregulation of CHOP 
 
As palmitic acid induced podocyte death involves ER-stress and as CHOP gene silencing 
attenuates palmitic acid induced podocyte death (Sieber et al., 2010), I investigated the effect 
of Aicar on the ER chaperone BiP and the proapoptotic transcription factor CHOP. Aicar 
strongly suppressed the upregulation of BiP and CHOP (Figure 28A, and B). (Sieber et al., 
2010)  
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Figure 28: Aicar mitigates palmitic acid induced ER-stress. A: Aicar attenuated palmitic acid-induced induction 
of CHOP and BiP after 24 hours. CHOP and BIP levels were analyzed by Western immunoblotting. ß-actin 
served as a loading control. B: Quantification of CHOP and BIP levels. Bar graph represents the relative mean 
expression levels ± SD (n = 3, ** p < 0.01). BSA treated controls were set to 100%.    
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4. DISCUSSION 
	
  
4.1. Aggravation of palmitic acid induced podocyte death by high glucose, 
TGF-β, and TNF-α 
	
  
Podocytopathy and loss occur at the onset of DN, predict progressive kidney disease (Meyer 
et al., 1999). Multiple factors of the diabetic milieu have been reported to induce podocyte 
death, including high glucose concentrations (Susztak et al., 2006), TGF-β (Schiffer et al., 
2001), and TNF-α (Ryu et al., 2012; Tejada et al., 2008) . Our group previously reported that 
podocytes are highly susceptible to palmitic acid induced cell death (Sieber et al., 2010). 
Importantly, palmitic acid induces podocyte death at relatively low concentration starting 
from 125µM, a concentration which is well within the reported physiological range of 120 to 
340 µM (Fraser et al., 1999; Groop et al., 1989; Hagenfeldt et al., 1972). In vivo, likely 
multiple factors contribute to podocyte death, and this was the reason why I explored to which 
extent palmitic acid modifies the response of podocyte to previously reported proapoptotic 
factors such as high glucose levels, TGF-β, and TNF-α. 
 
First, I observed that the effect of palmitic acid per se on podocyte death was strong, very 
robust, and independent of glucose concentrations, a result which further confirms the strong 
and very robust effect of palmitic acid on podocyte death (Sieber et al., 2010). Interestingly, I 
observed that a high glucose concentration of 22mM compared to a normal glucose 
concentration defined as 11mM, which is the concentration in most cell culture media had no 
or only a weak effect on podocyte death (figure 9). Contrariwise, the toxicity of 22mM 
glucose was very well visible in the presence of palmitic acid with a significant increase of 
apoptotic podocytes (figure 9). Previously we reported that the increase of necrotic podocytes 
can be underestimated, in particular if the necrosis level is already high (Sieber et al., 2010), 
as necrotic cells break apart and cannot be recovered for the cell death assay. This may 
explain why the increase could only be seen for apoptotic, and not necrotic podocytes. It is 
not clear why the effect of high glucose compared to normal glucose was difficult to see in 
the absence of palmitic acid, and this was in contrast to previous studies (Susztak et al., 2006). 
Possibly BSA as a control for palmitic acid complexed to BSA did account for this difference 
although in preliminary experiments without BSA the effect of high glucose alone was also 
not clearly visible. Certainly methodological differences may also explain these discrepancies. 
Further studies will be needed clarify this issue. 
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Next, I studied the effect of TGF-β in the presence and absence of palmitic acid. The effect of 
TGF-β alone on podocyte death was minimal and did not reach statistical significance (figure 
10). In contrast, the toxicity of TGF-β was highly significant in the presence of palmitic acid 
(figure 10). Why the effect of TGF-β alone was weak is not clear, and contrast previous 
reports (Schiffer et al., 2001). More studies are needed, and in particular the mechanisms for 
the increased toxicity of TGF-β in podocyte exposed to palmitic acid will be interesting to 
study in the future. 
 
The effect of TNF-α on podocyte was robust (figure 11) as reported previously (Ryu et al., 
2012; Tejada et al., 2008). In the presence of palmitic acid the additional increase was of 
modest and only visible for apoptotic podocytes. As mentioned previously, the reason that the 
effect was not seen for necrotic podocytes may be related to incomplete recovery of necrotic 
cells (Sieber et al., 2010). 
 
In summary, the results reported here are interesting and suggest that FFAs as palmitic acid 
can substantially aggravate the toxicity of other factors which are thought to be important in 
the pathogenesis of DN and which contribute to podocyte loss. 
 
4.2. Regulation of fatty acid oxidation in palmitic acid induced podocyte 
death: critical role of acetyl CoA carboxylase 1 and 2 
 
The study uncovers that in the glomeruli of type 2 diabetic patients with DN mRNA 
expression levels of several key enzymes involved in fatty acid metabolism are altered. Of 
particular relevance for the current work, a significant upregulation of all three isoforms of 
CPT-1, the rate-limiting enzyme for fatty acid oxidation, and a downregulation of ACC-2, 
which catalyzes the formation of the CPT-1 inhibitor malonyl-CoA, is found which suggests a 
disposition for increased fatty acid oxidation. Together with the detailed in vitro studies 
discussed below, this changed expression profile most likely suggests a compensatory, 
protective response. 
 
Furthermore, several lines of evidence indicate that regulation of FAO and interference with 
the AMPK-ACC-CPT-1 pathway affects podocytes exposed to palmitic acid. Specifically, the 
AMPK agonist Aicar, which significantly stimulates FAO in podocytes, reduces palmitic 
acid-induced podocyte death (figure 15). Conversely, the AMPK inhibitor compound C 
increased palmitic acid-induced cell death (figure 18). Furthermore, the CPT-1 inhibitor 
etomoxir, which completely prevents the Aicar induced increase of FAO in podocytes, 
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potentiates the toxicity of palmitic acid and dose-dependently reverses the protective effect of 
Aicar (figure 20). Moreover, gene silencing of ACC1/ACC2 markedly reduced palmitic acid-
induced cell death (figure 25).  
 
Adiponectin, a physiological activator of AMPK in podocytes (Sharma et al., 2008), also 
reduced palmitic acid-induced podocyte death (figure 16). Although its protective effect was 
relatively small compared to pharmacological activation by Aicar, the sustained action of 
adiponectin in vivo may still be relevant for the protection of podocytes from lipotoxicity. 
Activation of AMPK by adiponectin or Aicar is also reported to suppress oxidative stress and 
the NADPH oxidase Nox4 (Sharma et al., 2008). As neither tempol, a membrane-permeable 
radical scavenger, nor the antioxidant N-acetylcysteine reduce palmitic acid-induced podocyte 
death (unpublished observation), the modulation of oxidative stress through the AMPK 
pathway related to lipotoxicity needs further investigation. 
 
To further address the role of AMPK for palmitic acid-induced podocyte death we 
additionally used the AMPK inhibitor compound C which increased the toxicity of palmitic 
acid (figure 18). Compound C reduced the Aicar induced phosphorylation of ACC (figure 17) 
and partially prevented the protective Aicar effect (figure 18). Together, these findings 
suggest that the susceptibility of podocytes exposed to palmitic acid can be greatly modulated 
by AMPK.  
 
The present results indicating an important role of FAO and the AMPK-ACC-CPT-1 pathway 
for the susceptibility of podocytes exposed to toxic FFAs extend and potentially explain the 
results of recent GWAS which found a SNP in ACC2 with a significant enhancer activity 
resulting in an increased ACC2 expression associated with proteinuria in type 2 diabetic 
patients (Maeda et al., 2010; Tang et al., 2010). Moreover the results of this study suggest that 
the recently published observation of a decreased expression of ACC2 and an increased 
expression of all CPT-1 isoforms in glomerular extracts of type 2 diabetic patients (Sieber et 
al., 2013) reflects an adaptive, protective mechanism against toxic FFAs in DN. 
 
The differential role of ACC1 and ACC2 for the regulation of FAO is under debate (Olson et 
al., 2010). I found that only double knockdown of ACC1 and ACC2 has a protective effect on 
palmitic acid-induced cell death (figure 25). This indicates that both isoforms contribute to the 
inhibition of CPT-1 in podocytes as previously suggested for hepatocytes and skeletal muscle 
cells (Olson et al., 2010; Savage et al., 2006).  
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Interestingly, Aicar showed a small residual protective effect in ACC1/ACC2 double 
knockdown podocytes (figure 27). This may be due to residual expression of ACC-isoforms 
or an additional ACC independent effect. Activation of AMPK stimulates e. g.  peroxisome 
proliferator-activated receptor-gamma coactivator (PGC)-1α (Iwabu et al., 2010) which has 
been shown to be important for mitochondrial function in podocytes (Yuan et al., 2012). 
Finally, AMPK-independent off-target effects of Aicar cannot be excluded. Future studies are 
needed to confirm or refute this hypothesis. 
 
The biguanide metformin is widely used to treat type 2 diabetes (Qaseem et al., 2012). Its 
mechanism of action is not fully established but is reported to involve indirect activation of 
the AMPK-ACC-CPT-1 pathway via inhibition of complex I of the respiratory chain and a 
consequent increase in the AMP:ATP ratio which results in AMPK activation (Zang et al., 
2004). Despite this potential mode of action, preliminary experiments showed that metformin 
from 0.5-2 mM displays no protection from palmitic acid-induced lipotoxicity in podocytes 
(data not shown). Previously, undesired effects of metformin leading to cell death have been 
reported for pancreatic β-cells (Kefas et al., 2004). Of interest, a potential beneficial effect of 
metformin was shown in podocytes exposed to high glucose concentration of 30 mM by 
decreasing ROS production through reduction of NAD(P)H oxidase activity (Piwkowska et 
al., 2010). Clearly, more studies are required to reassess the short and long time effects of 
metformin on podocytes. 
 
Interestingly, Aicar significantly reduces the induction of CHOP in podocytes exposed to 
palmitic acid (figure 28), which is likely contributes to the  protective effect of Aicar as gene 
silencing of CHOP attenuates palmitic acid-induced cell death (Sieber et al., 2010). The 
action of Aicar on the AMPK-ACC-CPT-1 pathway may indicate that increased FAO reduces 
palmitic acid derived toxic metabolites and therefore suppresses the induction of ER-stress. 
However, the basic unanswered question is how palmitic acid and its metabolites trigger ER-
stress. Some reports indicated that palmitic acid rapidly increases the saturated lipid content 
of the ER leading to compromised ER morphology and integrity (Borradaile et al., 2006). In 
pancreatic β-cells palmitic acid depletes ER Ca2+ and slows ER Ca2+ uptake (Cunha et al., 
2008) which leads to accumulation of unfolded proteins. However, the detailed molecular 
mechanisms are not well known (Back et al., 2012). Clearly, more experiments are needed to 
understand these principle mechanisms and to study whether FAO and ER-stress are 
causatively related. 
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5. CONCLUSION 
	
  	
  	
  	
  	
  	
  	
  
The present study emphasizes the critical role of FFAs and FFA metabolism for podocyte 
survival. As loss of podocytes critically determines the pathogenesis and progression of DN, 
the findings contribute to a better understanding of the most common cause leading to ESRD.  
The results reported here suggest that palmitic acid significantly aggravates the toxicity of 
other factors such as high glucose concentrations and TGF-β, as their effect on podocyte 
death was largely increased in the presence of palmitic acid. 
 
My results suggest that modulation of FFA metabolism and stimulating FAO by activation of 
the AMPK-ACC-CPT-1 pathway critically influences the susceptibility of podocytes exposed 
to toxic FFAs. Together with our previous studies the following working model is suggested 
(Figure 29). Palmitic acid increases the generation of toxic metabolites, which leads to ER-
stress and podocyte death (Sieber et al., 2010). Oleic acid or induction of Scd-1/-2 expression 
by the LXR-agonists TO and GW shift palmitic acid and its metabolites into a “safe lipid 
pool” containing triglycerides (TG), which reduces injurious metabolites and prevents 
podocyte death (Sieber et al., 2013). In addition, activation of the AMPK-ACC-CPT-1 
pathway by Aicar reduces palmitic acid-induced podocyte death by increasing FAO and 
reducing palmitic acid and its metabolites. Our findings may explain the results of recent 
genome wide association studies indicating that modulation of FFA metabolism and 
specifically modulation of FAO directly affects the susceptibility to DN. In addition, our 
results have potentially important therapeutic implications to prevent and treat DN in type 2 
diabetic patients. 
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Figure 29: A working model for the Aicar activated AMPK-ACC-CPT-1 pathway and the prosurvival effects of 
oleic acid and Scd-1/-2 on palmitic acid-induced podocyte death. Palmitic acid increases the generation of toxic 
metabolites, which leads to ER-stress and podocyte death. The LXR-agonists TO and GW increase Scd-1/2 
expression, which in turn elevates the TG safe pool and reduces injurious metabolites and subsequent podocyte 
death. Similarly, oleic acid ameliorates palmitic acid-induced podocyte death by shifting palmitic acid and toxic 
metabolites to the TG safe pool. Additionally, Aicar reduces palmitic acid-induced podocyte death by 
stimulation of the AMPK-ACC-CPT-1 pathway and subsequently β-oxidation, thus decreasing toxic metabolites 
and eventually podocyte  
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Kampe K, Sieber J, Orellana JM, Mundel P, Jehle AW.
Susceptibility of podocytes to palmitic acid is regulated by fatty
acid oxidation and inversely depends on acetyl-CoA carboxylases
1 and 2. Am J Physiol Renal Physiol 306: F401–F409, 2014. First
published December 11, 2013; doi:10.1152/ajprenal.00454.2013.—
Type 2 diabetes is characterized by dyslipidemia with elevated free
fatty acids (FFAs). Loss of podocytes is a hallmark of diabetic
nephropathy, and podocytes are susceptible to saturated FFAs, which
induce endoplasmic reticulum (ER) stress and podocyte death. Ge-
nome-wide association studies indicate that expression of acetyl-CoA
carboxylase (ACC) 2, a key enzyme of fatty acid oxidation (FAO),
is associated with proteinuria in type 2 diabetes. Here, we show
that stimulation of FAO by aminoimidazole-4-carboxamide-1!-D-
ribofuranoside (AICAR) or by adiponectin, activators of the low-
energy sensor AMP-activated protein kinase (AMPK), protects from
palmitic acid-induced podocyte death. Conversely, inhibition of car-
nitine palmitoyltransferase (CPT-1), the rate-limiting enzyme of FAO
and downstream target of AMPK, augments palmitic acid toxicity and
impedes the protective AICAR effect. Etomoxir blocked the AICAR-
induced FAO measured with tritium-labeled palmitic acid. The ben-
eficial effect of AICAR was associated with a reduction of ER stress,
and it was markedly reduced in ACC-1/-2 double-silenced podo-
cytes. In conclusion, the stimulation of FAO by modulating the
AMPK-ACC-CPT-1 pathway may be part of a protective mechanism
against saturated FFAs that drive podocyte death. Further studies are
needed to investigate the potentially novel therapeutic implications of
these findings.
diabetic nephropathy; AMPK; apoptosis; !-oxidation; palmitic acid
DIABETIC NEPHROPATHY (DN) has become the primary cause of
end-stage renal disease (ESRD), and most affected patients
have type 2 diabetes (1, 15). Podocyte injury and loss are
critical events in the course of DN (31) and precede albumin-
uria (6, 17, 21). Type 2 diabetes mellitus is characterized by
hyperglycemia and dyslipidemia with increased plasma levels
of free fatty acids (FFAs) (24). In the kidneys of diabetic
humans, intraglomerular lipid deposits were already described
in 1936 by Kimmelstiel and Wilson (14). However, the poten-
tial role of FFAs and fatty acid metabolism in the pathogenesis
of DN is only emerging.
Previously, we reported that podocytes are highly suscepti-
ble to the saturated FFA palmitic acid but not to monounsat-
urated FFAs (MUFAs), such as oleic acid, which attenuate
palmitic acid-induced lipotoxicity (27). Mechanistically,
palmitic acid-induced podocyte death is linked to endoplasmic
reticulum (ER) stress involving the proapoptotic transcription
factor C/EBP homologous protein (CHOP) (27). In addition,
we reported that the gene expression of key enzymes of fatty
acid metabolism is altered in glomeruli of type 2 diabetic
patients with DN (29). Specifically, we found that stearoyl-
CoA desaturases 1 (SCD-1), the enzyme converting saturated
FFAs to MUFAs, is upregulated in podocytes. Functionally,
stimulation of Scds by the liver X receptor (LXR) agonists
TO901317 (TO) and GW3965 (GW) as well as overexpression
of Scd-1 were shown to be protective for palmitic acid-induced
podocyte death. Importantly, the previously reported changed
glomerular gene expression pattern (29) also suggests disposi-
tion for increased fatty acid !-oxidation (FAO) as all three
isoforms of carnitine palmitoyltransferase (CPT)-1, the rate-
limiting enzyme for FAO, were upregulated and acetyl-CoA
carboxylase (ACC) 2, which catalyzes the formation of the
CPT-1 inhibitor malonyl-CoA, was downregulated (29).
In humans and rodents, there are two ACC isoforms, ACC1
(ACC ") and ACC2 (ACC !) (25), which share considerable
sequence identity and the same domain structure responsible
for enzyme activity (25). In contrast to ACC1, ACC2 has an
extra N-terminal hydrophobic domain, which facilitates its
localization to the mitochondrial membrane (2), where it pref-
erentially regulates local malonyl-CoA levels and CPT-1 ac-
tivity. In contrast, cytosolic ACC1 is classically thought to
regulate malonyl-CoA synthesis for incorporation into fatty
acids in lipogenic tissues. However, more recently this classi-
cal view has been challenged, and at least in some cell types,
e.g., hepatocytes, both isoforms have been shown to regulate
CPT-1 activity synergistically (25).
A key regulator of FAO is the low-energy sensor AMP-
activated protein kinase (AMPK). Increased levels of AMP
lead to AMPK activation, which finally triggers ATP produc-
tion (10). AMPK directly targets and inactivates ACC by
phosphorylation (18). The inactivation of ACC prevents the
formation of malonyl-CoA (19) and thereby disinhibits CPT-1.
Importantly, two recent genome-wide association studies in
type 2 diabetic patients found a polymorphism in a noncoding
region of ACC2 with a strong association with proteinuria (16,
30). The DN-risk single nucleotide polymorphism of ACC2
results in a higher ACC2 expression (16) potentially leading to
decreased FAO and accumulation of toxic FFAs and their
deleterious metabolites.
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The objective of the present study was to investigate the
effect of FAO on the susceptibility of podocytes to palmitic
acid. Stimulation of FAO by the AMPK agonist aminoimida-
zole-4-carboxamide-1!-D-ribofuranoside (AICAR) was shown
to protect from palmitic acid-induced cell death whereas inhi-
bition of FAO by the CPT-1 inhibitor etomoxir enhanced the
toxicity of palmitic acid. In addition, the functional role of the
AMPK-ACC-CPT-1 pathway was assessed by gene silencing
of ACC1 and ACC2.
MATERIALS AND METHODS
Materials. Palmitic acid (P9767), fatty acid free-BSA (A8806),
etomoxir (E1905), compound C (P5499), and !-actin antibody
(A5441) were purchased from Sigma (St. Louis, MO). Recombinant
murine IFN-" (CTK-358-2PS) was from MoBiTec (Goettingen, Ger-
many). Type 1 collagen was from BD Biosciences. Annexin
V (A23204) and propidium iodide (PI; P3566) were from Invitrogen
(Eugene, OR). AICAR (no. 9944) and pAMPK (no. 2531), AMPK
(no. 2532), pACC (no. 3661), ACC (no. 3676), and immunoglobulin
heavy chain binding protein (BiP; no. 3183) antibodies were from Cell
Signaling Technology. CHOP (sc-7351) antibody was from Santa
Cruz Biotechnology (Dallas, TX). Adiponectin (no. 4902-100) was
purchased from BioVision (Milpitas, CA). The horseradish peroxi-
dase-conjugated secondary antibodies for rabbit and mouse were from
Dako. Tritium-labeled palmitic acid (NET043001MC) was from
PerkinElmer (Schwerzenbach, Switzerland).
Cell culture, free fatty acid preparation, and apoptosis assay.
Murine podocytes were cultured as described before (27). Podocytes
were differentiated for at least 11 days before the start of experiments.
All experiments were carried out in six-well plates except for isolating
protein or RNA for which 10-cm dishes were used. Free fatty acid
preparations were done as described previously (27). The palmitic
acid concentration used in this study was 200 #M complexed to BSA
(0.2%), which is within the reported physiological range of 120–340
#M (7–9). Endotoxin concentration was equal or less than 0.5 ng/ml,
as determined by a kit (no. L00350) from Genscript (Piscataway,
NJ). Annexin V and PI stainings were performed as reported earlier
(27). Flow cytometry was carried out with a CyAn ADP Analyzer
(Beckman Coulter), and 20,000 cells were counted. Data from flow
cytometry were analyzed by the FLOWJO (Tree Star, Ashland, OR)
software program. Annexin V-positive/PI-negative podocytes were
considered apoptotic, whereas annexin V-positive/PI-positive podo-
cytes were considered (late apoptotic) necrotic cells (27).
Plasmids, RNA-mediated interference, and viruses. ACC1 and
ACC2 genes were silenced by employing the following short hairpin
(sh) RNA sequences (12): ACC1, 5=-GCAGATTGCCAACATC-
CTAGA-3= and ACC2, 5=-GTGGTGACGGGACGAGCAA-3=. A
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Fig. 1. Aminoimidazole-4-carboxamide-1!-D-ribofuranoside (AICAR) and adiponectin protect podocytes from palmtic acid-induced cell death. A: metabolic
pathway activated by AICAR and adiponectin, which results in stimulation of fatty acid oxidation. CPT-1, carnitine palmitoyltransferase. B: immunoblot showing
phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) after incubation of podocytes with either (PBS) vehicle or 0.5 mM AICAR for 14 h. Total AMPK
and total ACC served as loading controls. C: AICAR attenuated palmitic acid-induced cell death. Values are mean percentages $ SD of apoptotic and necrotic
cells after 48 h (n % 3, *P & 0.05, **P & 0.01). D: 0.5 #g/ml adiponectin decreased palmitic acid-induced apoptosis and necrosis of podocytes. NS, not
significant. Values are mean percentages $ SD of apoptotic and necrotic cells after 48 h (n % 3, *P & 0.05).
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21-nt scrambled sequence (5=-GACCGCGACTCGCCGTCTGCG-3=)
(29) served as a control. ACC1, ACC2, and scrambled shRNA
sequences were cloned into a pSIH-H1 lentiviral expression plasmid.
A four-plasmid lentiviral system was used with following helper
plasmids: pRSV-REV (Rev expression vector), pMDLg/pRRE (Gag-
Pol expression vector), and pMD2.G (VSV-G expression vector). All
four plasmids were transfected to HEK cells via the FuGene HD
(Promega, Madison, WI) transfection agent, and the medium was
changed after 12 h. Forty-eight hours posttransfection, the supernatant
enriched with lentiviral particles was harvested, spun at 780 g for 5
min, and filtered through 0.45-!m filter. Transduction of podocytes
was done by pretreating podocytes with 5 !g/ml polybrene (Sigma).
All functional experiments were started after 4 days of transduction.
Western blotting. Western blotting was done as described before
(27). Antibodies against pAMPK, AMPK, pACC, ACC, CHOP, BiP,
and "-actin were employed at 1:250, 1:1,000, 1:500, 1:1,000, 1:1,000,
1:500, and 1:100,000 dilutions, respectively. Secondary antibodies for
rabbit and mouse were employed at 1:1,600 and 1:4,000 dilutions,
respectively.
Measuring oxidation of palmitic acid (!-oxidation). For these
experiments, podocytes were pretreated with AICAR for 1 h. Podo-
cytes were incubated with 200 !M palmitic acid in a serum starvation
medium (0.2% FBS, 5 mM glucose) supplemented with 0.5% FFA-
free BSA along with 0.5 !Ci/ml 3H-palmitic acid. Supernatants were
collected followed by chloroform/methanol/5 N HCl (2:1:0.05,
vol/vol) extraction. Four hundred microliters of the aqueous phase
(containing 3H2O) was added to 2 ml of scintillation buffer before
measurement of radioactivity.
Statistical analysis. All experiments were performed at least four
times, and a representative experiment is shown. Individual experi-
ments were performed in triplicate if not otherwise indicated. Data are
expressed as means # SD unless otherwise indicated. ANOVA and
Bonferroni t-tests were used for statistical analysis. The Prism 6
program was used for this analysis, and differences were considered
significant when the P value was $0.05.
RESULTS
AICAR protects from palmitic acid-induced podocyte death.
To investigate whether stimulation of FAO plays a protective
role in palmitic acid-treated podocytes, we took advantage of
the AMPK activator AICAR. AICAR acts by phosphorylating
AMPK, which in turn phosphorylates and inhibits ACC, re-
sulting in disinhibition of CPT-1 (see Fig. 1A). Phosphoryla-
tion of AMPK and ACC by AICAR in podocytes was exam-
ined by Western immunoblotting (Fig. 1B). As shown in Fig.
1C, AICAR significantly prevented palmitic acid-induced
podocyte death assessed by flow cytometry after staining for
annexin V and PI. Specifically, AICAR reduced palmitic acid-
induced apoptosis (annexin V single-positive cells) and necro-
sis (annexin V/PI double-positive cells) by 50.5 # 1.5 (P $
0.01) and 42.5 # 6.1% (P $ 0.05), respectively. Similarly, the
physiological AMPK agonist adiponectin (26) also reduced
palmitic acid-induced podocyte death, although to a lesser
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Fig. 2. Compound C aggravates palmitic acid-induced podocyte death and partially reverses the protective AICAR effect. A: podocytes were incubated for 14
h with DMSO (control), 0.5 mM AICAR, or 0.5 mM AICAR and 4 !M compound C. pACC and ACC levels were analyzed by Western immunoblotting.
B: quantification of pACC and ACC by densitometry. Values are mean relative expression # SD (* P $ 0.05). DMSO-treated controls were set to 100%.
C: compound C increased palmitic acid-induced podocyte death and partially reversed the protection of AICAR. Values are mean percentages# SD of apoptotic
and necrotic cells after 24 h (n % 3, **P $ 0.01).
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extent than AICAR. Figure 1D shows that adiponectin de-
creased both apoptosis and necrosis by 14.1 ! 4.7 (P " 0.05)
and 9.9! 6.3% (NS), respectively. To see the protective effect
of adiponectin, podocytes were kept at a high glucose concen-
tration of 22 mmol/l, which is known to reduce phosphoryla-
tion of AMPK (26) and increase the susceptibility of podocytes
to AMPK activation (26).
Compound C aggravates palmitic acid-induced podocyte
death and partially reverses the protective AICAR effect. To
further explore the role of AMPK we used the AMPK inhibitor
compound C. Compound C was used at a low concentration of
4 #M, and incubation time was limited to 24 h maximally, as
higher concentrations and longer exposure times were toxic;
i.e., podocyte death was markedly increased for BSA control
(data not shown). The AICAR-induced ACC phosphorylation
was significantly reduced by compound C (Fig. 2, A and B,
P " 0.05). Compound C increased palmitic acid-induced
apoptosis by 140.1! 20.1% (P" 0.01) and necrosis by 130.9!
14.0% (P " 0.01) (Fig. 2C). In agreement with the partial
reduction of the AICAR-induced ACC phosphorylation, com-
pound C compared with AICAR alone only moderately in-
creased palmitic acid-induced podocyte death; i.e., apoptosis
was increase by 128.2 ! 9.3 (NS) and necrosis by 176.7 !
9.7% (P " 0.01), respectively.
Etomoxir aggravates palmitic acid-induced podocyte death
and reverses the protective AICAR effect. To further investi-
gate the impact of FAO on palmitic acid-induced podocyte
death, we made use of the CPT-1 inhibitor etomoxir (Fig. 3A).
Etomoxir exacerbated palmitic acid-induced podocyte death
(Fig. 3B). Specifically, apoptosis was increased by 184.3! 6.0
(P " 0.01) and necrosis by 185.1 ! 16.3% (P " 0.01),
respectively. Moreover, etomoxir reversed the protective effect
of AICAR (Fig. 3C). Of note, this effect could already be seen
at a very low etomoxir concentration (10 #M), which by itself
had no significant effect on palmitic acid-induced podocyte
death (data not shown). Compared with podocytes treated with
AICAR alone, the presence of 10 #M etomoxir increased
palmitic acid-mediated apoptosis by 131.1 ! 5.0 (P " 0.05)
and necrosis by 127.3 ! 10.7% (P " 0.05), respectively. At
200 #M, etomoxir completely reversed the protective effect of
AICAR (Fig. 3C). The experiments using AICAR, compound
C, and etomoxir suggest an important role of the AMPK-ACC-
CPT-1 pathway for regulating the susceptibility of podocytes
exposed to palmitic acid.
AICAR increases and etomoxir inhibits oxidation of palmitic
acid in podocytes. To directly measure the effect of AICAR on
palmitic acid oxidation, we treated podocytes with 200 #M
palmitic acid along with 0.5 #Ci/ml tritiated palmitic acid in
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Fig. 3. Etomoxir exacerbates palmitic acid-induced podocyte death and reverses the protective effect of AICAR. A: mechanism of action of etomoxir, which
inhibits CPT-1 and thereby fatty acid oxidation. B: etomoxir aggravated palmitic acid-induced podocyte death after 48 h. Values are mean percentages ! SD
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the absence or presence of AICAR. As a direct readout of
palmitic acid !-oxidation, we measured tritiated water released
in the supernatants of podocytes. As expected, the release of
tritiated water gradually increased from 1 to 3 h (Fig. 4A). The
stimulation of podocytes with AICAR significantly increased
the formation of tritiated water (146.6" 22.0%, P# 0.05, Fig.
4A), reflecting the stimulatory effect of AICAR on palmitic
acid oxidation. Importantly, and as shown in Fig. 4B, the effect
of AICAR could be completely prevented by etomoxir.
AICAR significantly reduces ER stress and upregulation of
the proapoptotic transcription factor CHOP. As palmitic acid-
induced podocyte death involves ER stress and as CHOP gene
silencing attenuates palmitic acid-induced podocyte death (27),
we next investigated the effect of AICAR on the ER chap-
erone BiP and the proapoptotic transcription factor CHOP.
AICAR strongly suppressed the upregulation of BiP and
CHOP (Fig. 5, A and B).
Combined gene silencing of ACC1 and ACC2 protects from
palmitic acid-induced podocyte death. Two recent genome-
wide association studies (16, 30) found a single nucleotide
polymorphism in ACC2, leading to increased ACC2 expres-
sion (16), to be associated with proteinuria in type 2 diabetic
patients. To investigate further the role of both ACC isoforms
in podocytes, we generated cells deficient in ACC1, ACC2, or
both by lentiviral infection using specific shRNAs. Knock-
down of ACC1 but not ACC2 strongly reduced the band
corresponding to both isoforms. The residual band seen in
ACC1 single-knockdown podocytes was almost completely
gone in ACC1/ACC2 double-knockdown cells. (Fig. 6A).
These data suggest that the expression level of ACC1 is much
higher than ACC2 in podocytes. Functionally, only double
knockdown of both isoforms significantly reduced palmitic
acid-induced podocyte death. Specifically, in ACC1/ACC2
double-knockdown podocytes, palmitic acid-induced apoptosis
and necrosis were reduced by 57.4 " 3.9 (P # 0.01) and 72.1 "
7.5% (P # 0.05), respectively, compared with podocytes
transfected with scrambled shRNA (Fig. 6B), whereas single
knockdown of ACC1 or ACC2 had no significant effect (Fig.
6C). These results are in complete agreement with results in
hepatocytes, which have shown that both ACC isoforms
regulate FAO (25). Of note, a residual protective effect of
AICAR was seen in ACC1/ACC2 double-silenced podo-
cytes (Fig. 6B).
DISCUSSION
The present study uncovered that regulation of FAO criti-
cally determines the susceptibility of podocytes exposed to
palmitic acid. Our findings are of clinical interest, and they
relevantly amend recent clinical and experimental studies in-
dicating a potentially important role of FFAs and FFA metab-
olism in the pathogenesis of DN.
Several lines of evidence indicate that regulation of FAO
and interference with the AMPK-ACC-CPT-1 pathway affects
podocytes exposed to palmitic acid. Specifically, the AMPK
agonist AICAR, which significantly stimulates FAO in podo-
cytes, reduces palmitic acid-induced podocyte death. Con-
versely, the AMPK inhibitor compound C increased palmitic
acid-induced cell death. Furthermore, the CPT-1 inhibitor
etomoxir, which completely prevents the AICAR-induced in-
crease in FAO in podocytes, potentiates the toxicity of palmitic
acid and dose dependently reverses the protective effect of
AICAR. Moreover, gene silencing of ACC1/ACC2 markedly
reduced palmitic acid-induced cell death.
Adiponectin, a physiological activator of AMPK in podo-
cytes (26), also reduced palmitic acid-induced podocyte death.
Although its protective effect was relatively small compared
with pharmacological activation by AICAR, the sustained
action of adiponectin in vivo may still be relevant for the
protection of podocytes from lipotoxicity. Activation of
AMPK by adiponectin or AICAR is also reported to suppress
oxidative stress and the NADPH oxidase Nox4 (26). As neither
tempol, a membrane-permeable radical scavenger, nor the
antioxidant N-acetylcysteine reduce palmitic acid-induced
podocyte death (unpublished observations, Sieber J.), the mod-
ulation of oxidative stress through the AMPK pathway related
to lipotoxicity needs further investigation.
To further address the role of AMPK in palmitic acid-
induced podocyte death, we additionally used the AMPK
inhibitor compound C, which increased the toxicity of palmitic
acid. In addition, compound C reduced the AICAR-induced
phosphorylation of ACC and partially prevented the protective
AICAR effect. Together, these findings suggest that the sus-
ceptibility of podocytes exposed to palmitic acid can be greatly
modulated by AMPK.
The present results indicating an important role of FAO and
the AMPK-ACC-CPT-1 pathway in the susceptibility of podo-
cytes exposed to toxic FFAs extend and potentially explain the
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results of recent genome-wide associations studies which
found a SNP in ACC2 with significant enhancer activity,
resulting in increased ACC2 expression associated with pro-
teinuria in type 2 diabetic patients (16, 30). Moreover, the
results of this study suggest that the recently published obser-
vation of decreased expression of ACC2 and increased expres-
sion of all CPT-1 isoforms in glomerular extracts of type 2
diabetic patients (29) reflects an adaptive, protective mecha-
nism against toxic FFAs in DN.
The differential role of ACC1 and ACC2 in the regulation of
FAO is under debate (20). We found that only double knock-
down of ACC1 and ACC2 has a protective effect on palmitic
acid-induced cell death. This indicates that both isoforms
contribute to the inhibition of CPT-1 in podocytes, as previ-
ously suggested for hepatocytes and skeletal muscle cells
(20, 25).
Interestingly, AICAR showed a small residual protective
effect in ACC1/ACC2 double-knockdown podocytes. This
may be due to residual expression of ACC isoforms or an
additional ACC-independent effect. Activation of AMPK stim-
ulates peroxisome proliferator-activated receptor-! coactivator
(PGC)-1" (11), for example, which has been shown to be
important for mitochondrial function in podocytes (32). Fi-
nally, AMPK-independent off-target effects of AICAR cannot
be excluded. Future studies are needed to confirm or refute this
hypothesis.
The biguanide metformin is widely used to treat type 2
diabetes (23). Its mechanism of action is not fully established
but is reported to involve indirect activation of the AMPK-
ACC-CPT-1 pathway via inhibition of complex I of the respi-
ratory chain and a consequent increase in the AMP:ATP ratio,
which results in AMPK activation (33). Despite this potential
mode of action, preliminary experiments showed that met-
formin from 0.5 to 2 mM displays no protection from palmitic
acid-induced lipotoxicity in podocytes (data not shown). Pre-
viously, undesired effects of metformin leading to cell death
have been reported for pancreatic # cells (13). Of interest, a
potential beneficial effect of metformin was shown in podo-
cytes exposed to a high glucose concentration of 30 mM by
decreasing ROS production through reduction of NAD(P)H
oxidase activity (22). Clearly, more studies are required to
reassess the short- and long-term effects of metformin on
podocytes.
Interestingly, AICAR significantly reduces the induction of
CHOP in podocytes exposed to palmitic acid, which likely
contributes to the protective AICAR effect, as gene silencing
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of CHOP attenuates palmitic acid-induced cell death (27). The
action of AICAR on the AMPK-ACC-CPT-1 pathway may
indicate that increased FAO reduces palmitic acid-derived
toxic metabolites and therefore suppresses the induction of ER
stress. However, the basic unanswered question is how
palmitic acid and its metabolites trigger ER stress. Some
reports indicated that palmitic acid rapidly increases the satu-
rated lipid content of the ER, leading to compromised ER
morphology and integrity (4). In pancreatic ! cells, palmitic
acid depletes ER Ca2" and slows ER Ca2" uptake (5), which
leads to accumulation of unfolded proteins. However, the
detailed molecular mechanisms are not well known (3).
Clearly, more experiments are needed to understand these
principle mechanisms and to study whether FAO and ER stress
are causatively related.
In conclusion, our results suggest that modulation of FFA
metabolism and stimulation of FAO by activation of the
AMPK-ACC-CPT-1 pathway critically influence the sus-
ceptibility of podocytes exposed to toxic FFAs. Together
with our previous studies, the following working model is
suggested (Fig. 7). Palmitic acid increases the generation of
toxic metabolites, which leads to ER stress and podocyte
death (27). Oleic acid or induction of Scd-1/-2 expression by
the LXR-agonists TO and GW shift palmitic acid and its
metabolites into a “safe lipid pool” containing triglycerides
(TG), which reduces injurious metabolites and prevents
podocyte death (29). In addition, activation of the AMPK-
ACC-CPT-1 pathway by AICAR reduces palmitic acid-
induced podocyte death by increasing FAO and reducing
palmitic acid and its metabolites. Our findings may explain
the results of recent genome-wide association studies indi-
cating that modulation of FFA metabolism and specifically
modulation of FAO directly affects the susceptibility to DN.
In addition, our results have potentially important therapeu-
tic implications for the prevention and treatment of DN in
type 2 diabetic patients.
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